Loading...
Loading...
India's liraglutide imports from UNITED STATES total $466.7K across 79 shipments from 15 foreign suppliers. AGRACE PHARMA leads with $66.1K in import value; the top 5 suppliers together control 57.4% of this origin. Leading Indian buyers include EXTROVIS PRIVATE LIMITED. This corridor reflects India's pharmaceutical import demand for liraglutide — a diversified sourcing base with multiple active suppliers from UNITED STATES.

AGRACE PHARMA is the leading Liraglutide supplier from UNITED STATES to India, with import value of $66.1K across 20 shipments. The top 5 suppliers — AGRACE PHARMA, ESPEE BIOPHARMA AND FINECHEM LLC, RAFF & HALL PHARMACY,, SAVI CLINICALS FZ LLC, SUN PHARMACEUTICAL INDUSTRIES INC — collectively account for 57.4% of total import value from this origin.
Ranked by import value (USD) · Indian Customs (DGFT) data
| # | Supplier | Value (USD) | Shipments | Share |
|---|---|---|---|---|
| 1 | AGRACE PHARMA | $66.1K | 20 | 14.2% |
| 2 | ESPEE BIOPHARMA AND FINECHEM LLC | $60.0K | 7 | 12.9% |
| 3 | RAFF & HALL PHARMACY, | $48.1K | 2 | 10.3% |
| 4 | SAVI CLINICALS FZ LLC | $48.0K | 7 | 10.3% |
| 5 | SUN PHARMACEUTICAL INDUSTRIES INC | $45.4K | 2 | 9.7% |
| 6 | LENOX TERRACE PHARMACY INC | $38.9K | 3 | 8.3% |
| 7 | ESPEE BIOPHARMA & FINECHEM LLC | $38.6K | 6 | 8.3% |
| 8 | AGRACE PHARMA. | $33.0K | 8 | 7.1% |
| 9 | AMSTERDAM PHARMA(APTEKA RX INC.) | $15.2K | 3 | 3.3% |
| 10 | SPRING BIO SOLUTION | $15.0K | 2 | 3.2% |
| 11 | AMSTERDAM PHARMA APTEKA RX INC | $14.0K | 1 | 3.0% |
| 12 | CELTIS HEALTHCARE LLC | $13.7K | 4 | 2.9% |
| 13 | AMSTERDAM PHARMA (APTEKA RX INC.) | $6.2K | 2 | 1.3% |
| 14 | New City RX LLC | $5.9K | 1 | 1.3% |
| 15 | RAFF & HALL PHARMACY | $4.6K | 1 | 1.0% |
Ranked by import value (USD)
| # | Buyer | Value (USD) | Shipments | Share |
|---|---|---|---|---|
| 1 | EXTROVIS PRIVATE LIMITED | $65.6K | 7 | 14.1% |
| 2 | ZYDUS LIFESCIENCES LIMITED | $61.9K | 6 | 13.3% |
| 3 | DR.REDDY'S LABORATORIES LTD | $53.2K | 9 | 11.4% |
| 4 | ENZENE BIOSCIENCES LIMITED | $49.8K | 6 | 10.7% |
| 5 | BIOLOGICAL E. LIMITED | $46.7K | 7 | 10.0% |
| 6 | SUN PHARMACEUTICAL INDUSTRIES LIMITED | $45.4K | 2 | 9.7% |
| 7 | ORBICULAR PHARMACEUTICAL TECHNOLOGIES PRIVATE LIMI | $38.6K | 15 | 8.3% |
| 8 | LUPIN LIMITED | $25.2K | 5 | 5.4% |
| 9 | AUROBINDO PHARMA LIMITED | $17.1K | 2 | 3.7% |
| 10 | MSN LABORATORIES PRIVATE LIMITED | $15.3K | 1 | 3.3% |
| 11 | RELIANCE LIFE SCIENCES PRIVATE LIMITED | $13.1K | 3 | 2.8% |
| 12 | DR REDDY S LABORATORIES LTD | $10.5K | 3 | 2.3% |
| 13 | BIOLOGICAL E LTD | $7.2K | 1 | 1.5% |
| 14 | DR.REDDY'S LABORATORIES LIMITED | $5.2K | 1 | 1.1% |
| 15 | AUROBINDO PHARMA LTD | $4.7K | 3 | 1.0% |
Answers based on Indian Customs (DGFT) import records compiled by TransData Nexus
The top Liraglutide suppliers from UNITED STATES to India include AGRACE PHARMA, ESPEE BIOPHARMA AND FINECHEM LLC, RAFF & HALL PHARMACY,. The leading supplier is AGRACE PHARMA with import value of $66.1K USD across 20 shipments. India imported Liraglutide worth $466.7K USD from UNITED STATES in total across 79 shipments.
India imported Liraglutide worth $466.7K USD from UNITED STATES across 79 shipments. Data is from Indian Customs (DGFT) records. Values are in USD.
The main Indian buyers of Liraglutide sourced from UNITED STATES include EXTROVIS PRIVATE LIMITED, ZYDUS LIFESCIENCES LIMITED, DR.REDDY'S LABORATORIES LTD. The largest buyer is EXTROVIS PRIVATE LIMITED with $65.6K in imports across 7 shipments.
The total value of Liraglutide imports from UNITED STATES to India is $466.7K USD, across 79 shipments and 15 foreign suppliers. Data source: Indian Customs (DGFT).
Data sourced from Indian Customs (DGFT) records. Verify regulatory and trade status with the agencies above.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
79 Verified Shipments
15 suppliers, 15 buyers tracked
Expert-Reviewed
By pharmaceutical trade specialists